To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
9
Samsung Medical Center
Seoul, South Korea
Percentage of subjects with COVID-19
positive result in RT-PCR test
Time frame: Up to 14 days
Percentage of subjects with hospitalization
hospitalization due to COVID-19
Time frame: Days 3, 7, 14, and 28
Percentage of subjects who experience intensive care unit (ICU)
ICU requirement due to COVID-19
Time frame: Days 3, 7, 14, and 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.